Related Experiment Video
Updated: May 17, 2026
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
[Therapeutic response and survival in patients with hairy cell leukemia in a third level institution]
Karina Teresita González-Rodríguez1, Angel Gabriel Vargas-Ruiz, Xavier López-Karpovitch
1Departamento de Hematología y Oncología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador, Zubirán, México.
Background:
in Mexico published casuistry concerning hairy cell leukemia (HCL) is limited.
Objective:
to describe the therapeutic response and survival of patients with HCL attended in a third level public institution.
Methods:
patient's data with HCL diagnosis registered between January 1989 - December 2009 were analyzed.
Results:
twenty three patients fulfilled HCL diagnosis criteria. Median age was 44 years (range 23-75 years) and median follow-up of the cohort was 1,877 days (range 1-8,462 days). First line treatment varied along time finding complete response (CR) and partial response (PR) rates of 77.3 and 18.2%, respectively. Of all therapeutic modalities employed cladribine induced the highest response rate. Survival at 1,877 days was 82.6%. At last follow-up 65.2% of patients remain alive, 13 in CR and 2 in PR; 4 died (CR = 2, PR = 1, active disease = 1) and 4 were lost during follow-up.
Conclusion:
this study which included more patients than previous single-institution Mexican series confirm the chronic clinical behavior of HCL and that purine analogs are corner stone in the treatment of patients suffering HCL.
